TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25175981

Group type: EXPERIMENTAL
Intervention: Vildagliptin
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 15
Study: 22665593

Group type: EXPERIMENTAL
Intervention: BioSand filter (BSF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No BioSand filter (Control)
Number of subjects: 0
Study: 18977267

Group type: EXPERIMENTAL
Intervention: 11-valent pneumococcal conjugate vaccine (11PCV)
Number of subjects: 378
Study: 17186261

Group type: EXPERIMENTAL
Intervention: ICG 0.1% in glucose 5%
Number of subjects: 60

Group type: COMPARATOR
Intervention: No ICG
Number of subjects: 60
Study: 15133424

Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 0
Study: 11723385

Group type: EXPERIMENTAL
Intervention: High-dose methylprednisolone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9743162

Group type: EXPERIMENTAL
Intervention: Ozone exposure (mean level=120 ppb)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Filtered air exposure
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Ozone exposure
Number of subjects: 15
Study: 8061851

Group type: EXPERIMENTAL
Intervention: Spirapril
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 3058238

Group type: EXPERIMENTAL
Intervention: Tamoxifen and fluoxymesterone
Number of subjects: 63

Group type: COMPARATOR
Intervention: Tamoxifen and danazol
Number of subjects: 63
Study: 29746672

Group type: EXPERIMENTAL
Intervention: Sarilumab 200 mg q2w plus MTX
Number of subjects: 1197

Group type: EXPERIMENTAL
Intervention: Sarilumab 150 mg q2w plus MTX
Number of subjects: 1197

Group type: COMPARATOR
Intervention: Placebo plus MTX
Number of subjects: 1197

Group type: EXPERIMENTAL
Intervention: Sarilumab (both dosages)
Number of subjects: 1197
Study: 27165711

Group type: EXPERIMENTAL
Intervention: Edoxaban 90 mg/day for 10 days followed by 60 mg/day
Number of subjects: 85

Group type: COMPARATOR
Intervention: Parenteral anticoagulation bridging to warfarin for 3 months
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 85

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 85
Study: 26280592

Group type: EXPERIMENTAL
Intervention: Active treatment condition (AT; n = 31)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control treatment condition (CT; n = 31)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Both conditions (AT and CT)
Number of subjects: 62
Study: 23590301

Group type: EXPERIMENTAL
Intervention: PBMC gene expression profiles in smokers with COPD
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Candidate genes validated in independent cohort
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Plasma metabolomics
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Pathways analysis
Number of subjects: 136
Study: 20459731

Group type: EXPERIMENTAL
Intervention: Ischaemic preconditioning (IPC)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control
Number of subjects: 20
Study: 19808428

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 8828

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 8828

Group type: EXPERIMENTAL
Intervention: Higher HR on in-treatment ECGs
Number of subjects: 8828

Group type: EXPERIMENTAL
Intervention: Persistence or development of HR ≥84
Number of subjects: 8828

Group type: EXPERIMENTAL
Intervention: Higher in-treatment HR
Number of subjects: 8828
Study: 16650165

Group type: EXPERIMENTAL
Intervention: Desloratadine treatment for 4 weeks
Number of subjects: 10

Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 10
Study: 12118963

Group type: EXPERIMENTAL
Intervention: TPI (Thrombolytic Predictive Instrument)
Number of subjects: 1197

Group type: COMPARATOR
Intervention: Control
Number of subjects: 1197
Study: 10402447

Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft surgery (CABG)
Number of subjects: 550
Study: 7778523

Group type: EXPERIMENTAL
Intervention: Communication-games intervention with seven interactive elements drawn from the parent-child interaction literature
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study: 2080486

Group type: EXPERIMENTAL
Intervention: 1 tablet of althiazide (15 mg) and spironolactone (25 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 2 tablets of althiazide (15 mg) and spironolactone (25 mg)
Number of subjects: 12
Study: 492804

Group type: EXPERIMENTAL
Intervention: Methylphenidate 0.3 mg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methylphenidate 1.0 mg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31980138

Group type: EXPERIMENTAL
Intervention: Gender disparity perceptions among surgeons
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Concerns with gaps in mentoring
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Difficulties finding role models
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Sacrifices for professional advancement
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Perceived biases against female surgeons
Number of subjects: 36
Study: 29565195

Group type: EXPERIMENTAL
Intervention: Balloon-mediated labour induction
Number of subjects: 1971

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 (PGE2) agents - propess
Number of subjects: 1971

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 (PGE2) agents - prostin
Number of subjects: 1971

Group type: EXPERIMENTAL
Intervention: Combination of propess and prostin
Number of subjects: 1971

Group type: EXPERIMENTAL
Intervention: Quadruple combinations of induction modalities
Number of subjects: 1971
Study: 27581328

Group type: EXPERIMENTAL
Intervention: Biweekly phone-based group counseling
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mailed newsletters
Number of subjects: 0
Study: 23470116

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for anxiety
Number of subjects: 227

Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Number of subjects: 227
Study: 23496893

Group type: EXPERIMENTAL
Intervention: Online program including a physical activity lesson
Number of subjects: 512
Study: 20357375

Group type: EXPERIMENTAL
Intervention: Sitagliptin (4-week treatment)
Number of subjects: 32

Group type: COMPARATOR
Intervention: No additional treatment (Control)
Number of subjects: 32
Study: 18093679

Group type: EXPERIMENTAL
Intervention: Cheneau brace full-time (23/24 hours)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Cheneau brace part-time (night only)
Number of subjects: 108

Group type: COMPARATOR
Intervention: No brace (control group)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Cheneau brace (both full-time and part-time)
Number of subjects: 108
Study: 16155380

Group type: EXPERIMENTAL
Intervention: Milrinone in combination with inhaled nitric oxide (iNO)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Inhaled nitric oxide (iNO)
Number of subjects: 4
Study: 12862328

Group type: EXPERIMENTAL
Intervention: Malarone (atovaquone 250 mg/proguanil 100 mg)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Primaquine (30 mg of base)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Malarone and Primaquine
Number of subjects: 28
Study: 10979164

Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment on postoperative days 2 through 5
Number of subjects: 76
Study: 9117755

Group type: EXPERIMENTAL
Intervention: 5% Amlexanox paste
Number of subjects: 991
Study: 7686120

Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control
Number of subjects: 23
Study: 3555355

Group type: EXPERIMENTAL
Intervention: Hydrocolloid dressings (HCDs)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Dakin's solution (chloramine‐T)‐soaked wet‐to‐dry dressings
Number of subjects: 52
Study: 31618466

Group type: EXPERIMENTAL
Intervention: Skin-to-skin contact (SSC) with a parent
Number of subjects: 55

Group type: COMPARATOR
Intervention: Care on a resuscitaire and later in an incubator or bed
Number of subjects: 55
Study: 28811354

Group type: EXPERIMENTAL
Intervention: 4 mg QD
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: 8 mg QD
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Both doses
Number of subjects: 201
Study: 27180621

Group type: EXPERIMENTAL
Intervention: Simplified substrate ablation procedure with scar dechanneling as the first step (group 1)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Standard procedure with VT induction, mapping, and ablation followed by scar dechanneling (group 2)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Group 1 (after substrate ablation)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Group 2 (after substrate ablation)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: End-procedure success (after residual inducible VT ablation)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: VT recurrence rate
Number of subjects: 48
Study: 25525672

Group type: COMPARATOR
Intervention: WebChoice
Number of subjects: 167

Group type: COMPARATOR
Intervention: IPPC
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Usual care
Number of subjects: 167
Study: 22076246

Group type: EXPERIMENTAL
Intervention: 10 mg dexamphetamine
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 0.8 g/kg alcohol
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 10 mg dexamphetamine + 0.8 g/kg alcohol
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 20587954

Group type: EXPERIMENTAL
Intervention: Lateral condensation technique
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: BeeFill system
Number of subjects: 40

Group type: COMPARATOR
Intervention: Negative control group (lateral condensation technique)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Positive control group (not root‐filled)
Number of subjects: 40
Study: 18767576

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) at Zhongji (CV 3)
Number of subjects: 276

Group type: COMPARATOR
Intervention: Medication group with oral administration of Qianliekang tablets
Number of subjects: 276
Study: 15929961

Group type: EXPERIMENTAL
Intervention: Cystic fibrosis patients
Number of subjects: 104

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Cystic fibrosis patients with severe lung disease (FEV(1) <40% predicted)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Cystic fibrosis patients with mild or moderate pulmonary disease
Number of subjects: 104
Study: 12351296

Group type: EXPERIMENTAL
Intervention: Median approach transsacral epidural block (S2-3 group)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Caudal approach transsacral epidural block (caudal group)
Number of subjects: 30
Study: 9891521

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with carboplatin and ifosfamide (11 patients)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with carboplatin and paclitaxel (3 patients)
Number of subjects: 14

Group type: COMPARATOR
Intervention: No neoadjuvant chemotherapy (6 patients with no change)
Number of subjects: 14
Study: 7731896

Group type: EXPERIMENTAL
Intervention: Erythropoietin administration
Number of subjects: 30

Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Dialyzed patients with end stage renal failure
Number of subjects: 30
Study: 2691483

Group type: EXPERIMENTAL
Intervention: Single pre-operative dose of 2.2 g amoxycillin/clavulanate
Number of subjects: 467

Group type: COMPARATOR
Intervention: Combination of 1.5 g cefuroxime plus 0.5 g metronidazole
Number of subjects: 467
Study: 4932797

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulphamethoxazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sulphamethoxazole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 0
Study: 371733

Group type: EXPERIMENTAL
Intervention: Low osmolality contrast medium (sodium‐methyl‐glucamine‐ioxaglate)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Conventional compound (methylglucamine‐ioxitalamate)
Number of subjects: 12
Study: 31371432

Group type: EXPERIMENTAL
Intervention: Sotagliflozin 200 mg
Number of subjects: 1575

Group type: EXPERIMENTAL
Intervention: Sotagliflozin 400 mg
Number of subjects: 1575

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1575
Study: 28606661

Group type: EXPERIMENTAL
Intervention: VR training using Xbox Kinect plus conventional physical therapy (30 minutes each)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional physical therapy only (30 minutes)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: VR training using Xbox Kinect plus conventional physical therapy
Number of subjects: 20
Study: 25848859

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 26

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 26
Study: 23585422

Group type: EXPERIMENTAL
Intervention: Alcohol hand rub
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Povidone-iodine hand scrub
Number of subjects: 35

Group type: COMPARATOR
Intervention: Plain soap hand wash
Number of subjects: 35
Study: 21418260

Group type: EXPERIMENTAL
Intervention: Pancrelipase delayed-release capsules (Creon) at a mean dose of 186960±74640 lipase units/day
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Pancrelipase delayed-release capsules (Creon)
Number of subjects: 51
Study: 19238545

Group type: EXPERIMENTAL
Intervention: LIFT intervention
Number of subjects: 351
Study: 17365975

Group type: EXPERIMENTAL
Intervention: Thrombolysis followed by immediate coronary angiography and intervention
Number of subjects: 266

Group type: COMPARATOR
Intervention: Thrombolysis followed by conservative management
Number of subjects: 266
Study: 15084794

Group type: EXPERIMENTAL
Intervention: Donepezil (10 mg daily) plus cognitive training (images of everyday life and reminiscent music, 3 sessions per week for 12 months)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Donepezil (10 mg daily)
Number of subjects: 86
Study: 11284571

Group type: EXPERIMENTAL
Intervention: Operative treatment using a Herbert bone screw
Number of subjects: 61

Group type: COMPARATOR
Intervention: Conservative treatment using a cast
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Operative treatment
Number of subjects: 61
Study: 9526933

Group type: EXPERIMENTAL
Intervention: Ringer's acetate (AR)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ringer's lactate (LR)
Number of subjects: 60
Study: 7983221

Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing (EMD/R)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization with Music (EMD/M)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control
Number of subjects: 30
Study: 2519941

Group type: EXPERIMENTAL
Intervention: 1 gram of nafcillin in 10 mL of saline as an intravenous (IV) bolus
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 1 gram of nafcillin in 50 mL of saline as a slow IV infusion over 15 minutes
Number of subjects: 45

Group type: COMPARATOR
Intervention: No nafcillin administration (Control group)
Number of subjects: 45
Study: 5763961

Group type: EXPERIMENTAL
Intervention: Neostigmine given with atropine
Number of subjects: 46

Group type: COMPARATOR
Intervention: Neostigmine given after atropine
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Atropine given before or with neostigmine
Number of subjects: 46
Study: 31619654

Group type: EXPERIMENTAL
Intervention: Ultra-high hydrostatic pressurized brown rice (UHHPBR) intake group (n=20) consuming 100 g of UHHPBR and 100 g of white rice (WR) per day for 12 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: White rice (WR) intake group (n=20) consuming 200 g of WR per day for 12 months
Number of subjects: 40
Study: 28301687

Group type: EXPERIMENTAL
Intervention: Ozone therapy (OG; n=20) applied at the point of greatest pain, three times per week for a total of six sessions.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham ozone therapy (PG; n=20) applied at the point of greatest pain, three times per week for a total of six sessions.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ozone therapy (OG) at 3 months (T2) for temporal muscle PPT.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ozone therapy (OG) at 3 months (T2) for masseter muscle PPT.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ozone therapy (OG) at 3 months (T2) for lateral pole PPT.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ozone therapy (OG) for right lateral excursion at 3 months (T2).
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ozone therapy (OG) for overall VAS scores from baseline to 3 months.
Number of subjects: 40
Study: 25894894

Group type: EXPERIMENTAL
Intervention: JNJ-38893777 (doses: 5, 15, 45, 125, 250, or 500 mg)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: JNJ-38893777 (250 mg in fasting state and 250 mg, 375 mg, or 500 mg in high-fat fed state)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: JNJ-38893777
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 23562359

Group type: EXPERIMENTAL
Intervention: Ethanwell/Ethanzyme (EE) regimen enriched with omega‐3 fatty acids, micronutrients, and probiotics
Number of subjects: 68

Group type: COMPARATOR
Intervention: Isocal (control)
Number of subjects: 68
Study: 21429223

Group type: EXPERIMENTAL
Intervention: Single intradermal sterile water injection (SWI) technique
Number of subjects: 319

Group type: COMPARATOR
Intervention: Four intradermal sterile water injection (SWI) technique
Number of subjects: 319
Study: 19752426

Group type: EXPERIMENTAL
Intervention: Geographic atrophy (GA) area measurement using digitized fundus photographs
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Development of central GA
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Visual acuity measurement
Number of subjects: 181
Study: 16406154

Group type: EXPERIMENTAL
Intervention: Cingulate gyrus atrophy rates in AD
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Cingulate gyrus atrophy rates in FTLD
Number of subjects: 38

Group type: COMPARATOR
Intervention: Cingulate gyrus atrophy rates in controls
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Hippocampal atrophy rates in AD
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Hippocampal atrophy rates in FTLD
Number of subjects: 38

Group type: COMPARATOR
Intervention: Hippocampal atrophy rates in controls
Number of subjects: 38
Study: 15220018

Group type: EXPERIMENTAL
Intervention: Glimepiride + Pioglitazone (G + P)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Glimepiride + Rosiglitazone (G + R)
Number of subjects: 91
Study: 12456607

Group type: EXPERIMENTAL
Intervention: 10 mg mifepristone
Number of subjects: 3052

Group type: COMPARATOR
Intervention: 25 mg mifepristone
Number of subjects: 3052
Study: 9640189

Group type: EXPERIMENTAL
Intervention: Latanoprost monotherapy (50 micrograms/ml)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Dipivefrin monotherapy (1 mg/ml)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Combination therapy of latanoprost and dipivefrin
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Latanoprost and dipivefrin (combined)
Number of subjects: 22
Study: 7979527

Group type: EXPERIMENTAL
Intervention: 40 mg of cromoglycate three times a day by wet nebulisation (n = 16)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Physiological saline as placebo three times a day by wet nebulisation (n = 15)
Number of subjects: 31
Study: 2561597

Group type: EXPERIMENTAL
Intervention: Pyrophosphate/copolymer toothpaste
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 50
Study: 1147500

Group type: EXPERIMENTAL
Intervention: Intravenous diazepam preoperatively
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 31743136

Group type: EXPERIMENTAL
Intervention: Propofol (2 to 3 mg/kg)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Etomidate (0.2 to 0.3 mg/kg)
Number of subjects: 98
Study: 31285490

Group type: EXPERIMENTAL
Intervention: Social Skills Group Training (SSGT)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 207
Study: 26500228

Group type: EXPERIMENTAL
Intervention: Home detention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early work release
Number of subjects: 0

Group type: COMPARATOR
Intervention: Custody (Control Group)
Number of subjects: 0
Study: 26264550

Group type: EXPERIMENTAL
Intervention: Usual care plus DASH-based dietary counselling (n = 281)
Number of subjects: 556

Group type: COMPARATOR
Intervention: Usual care (standard education, control) (n = 275)
Number of subjects: 556
Study: 24060106

Group type: EXPERIMENTAL
Intervention: Tailored Activity Program
Number of subjects: 160

Group type: COMPARATOR
Intervention: Attention-control group (bi-monthly telephone contact)
Number of subjects: 160
Study: 20820791

Group type: EXPERIMENTAL
Intervention: Partial meal replacement diet containing a vegetable-oil emulsion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dairy fat (control)
Number of subjects: 0
Study: 19245687

Group type: EXPERIMENTAL
Intervention: Chloroquine
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: Amodiaquine
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: Sulphadoxine-pyrimethamine
Number of subjects: 455
Study: 17711691

Group type: EXPERIMENTAL
Intervention: Diver CE device
Number of subjects: 122

Group type: COMPARATOR
Intervention: Guardwire Plus device
Number of subjects: 122
Study: 15316094

Group type: EXPERIMENTAL
Intervention: Everolimus 0.75 mg/day
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Everolimus 2.5 mg/day
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Everolimus 5 mg/day
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg/day
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 11246591

Group type: EXPERIMENTAL
Intervention: Folic acid supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Multivitamins containing folic acid
Number of subjects: 0
Study: 9109044

Group type: EXPERIMENTAL
Intervention: Tirilazad mesylate 10.0 mg/kg/day for 5 days
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: U-89678 (active metabolite)
Number of subjects: 55
Study: 8110306

Group type: COMPARATOR
Intervention: Single-breast feeding
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Two-breast feeding
Number of subjects: 80